{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:37Z","timestamp":1790352157222,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2022-0140"],"award-info":[{"award-number":["6-2022-0140"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabet.2026.101787","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:48:18Z","timestamp":1786492098000},"page":"101787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lower glucagon response and attenuated hepatic glucagon signaling in MASLD"],"prefix":"10.1016","volume":"52","author":[{"given":"So Ra","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeseong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4992","authenticated-orcid":false,"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6219-4942","authenticated-orcid":false,"given":"Yong-ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101787_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2026.101787_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2026.101787_bib0003","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0004","doi-asserted-by":"crossref","first-page":"E671","DOI":"10.1152\/ajpendo.00492.2002","article-title":"Glucagon and regulation of glucose metabolism","volume":"284","author":"Jiang","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2026.101787_bib0006","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101787_bib0007","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101787_bib0008","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0009","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101787_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2026.101787_bib0011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1463-1326.2011.01549.x","article-title":"Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity","volume":"14","author":"Knop","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0012","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/db19-0715","article-title":"Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis","volume":"69","author":"Suppli","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0013","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2017-02014","article-title":"Patterns of plasma glucagon dynamics do not match metabolic phenotypes in young women","volume":"103","author":"Gar","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0014","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2337\/db16-0354","article-title":"Nonsuppressed glucagon after glucose challenge as a potential predictor for glucose tolerance","volume":"66","author":"Wagner","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/joim.12462","article-title":"Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia","volume":"279","author":"Junker","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabet.2026.101787_bib0016","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1111\/liv.14205","article-title":"Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion","volume":"39","author":"Eriksen","year":"2019","journal-title":"Liver Intern"},{"key":"10.1016\/j.diabet.2026.101787_bib0017","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1097\/MEG.0000000000002269","article-title":"Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression","volume":"33","author":"Wang","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0018","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4093\/dmj.2025.0469","article-title":"2025 Clinical practice guidelines for diabetes management in Korea: recommendation of the Korean Diabetes Association","volume":"49","author":"Kang","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabet.2026.101787_bib0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2026.101787_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI105534","article-title":"Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus","volume":"46","author":"Seltzer","year":"1967","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2026.101787_bib0021","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2666-7568(22)00247-1","article-title":"Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study","volume":"4","author":"Lopez-Jaramillo","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.diabet.2026.101787_bib0022","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Clinical","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2026.101787_bib0024","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0025","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.diabet.2026.101787_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jhep.2010.06.022","article-title":"Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis","volume":"54","author":"Gaia","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0027","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep4.1562","article-title":"Nonalcoholic fatty liver disease impairs the liver-alpha cell axis independent of hepatic inflammation and fibrosis","volume":"4","author":"Pedersen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.diabet.2026.101787_bib0028","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15653","article-title":"Postprandial dysfunction in fatty liver disease","volume":"11","author":"Grandt","year":"2023","journal-title":"Physiol Rep"},{"key":"10.1016\/j.diabet.2026.101787_bib0029","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-023-00817-4","article-title":"Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases","volume":"19","author":"H\u00e6dersdal","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2026.101787_bib0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41574-018-0097-y","article-title":"The \u03b1-cell in diabetes mellitus","volume":"14","author":"Gromada","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2026.101787_bib0031","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2026.101787_bib0032","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Clinical","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2026.101787_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874104501408010028","article-title":"Recent progress in the use of glucagon and glucagon receptor antago-nists in the treatment of diabetes mellitus","volume":"8","author":"Lotfy","year":"2014","journal-title":"Open Med Chem J"},{"key":"10.1016\/j.diabet.2026.101787_bib0034","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543776.2020.1769600","article-title":"Small molecule glucagon receptor antagonists: an updated patent review (2015-2019)","volume":"30","author":"Cheng","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.diabet.2026.101787_bib0035","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0036","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/13543784.2017.1395020","article-title":"Investigational glucagon receptor antagonists in phase I and II clinical trials for diabetes","volume":"26","author":"Scheen","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diabet.2026.101787_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.diabet.2026.101787_bib0038","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0039","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2337\/diab.23.9.725","article-title":"Effect of glucagon: insulin ratios on hepatic metabolism","volume":"23","author":"Parrilla","year":"1974","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0040","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.diabet.2026.101787_bib0041","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0042","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1113\/jphysiol.2006.121954","article-title":"High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise","volume":"579","author":"Charbonneau","year":"2007","journal-title":"J Physiol"},{"key":"10.1016\/j.diabet.2026.101787_bib0043","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0365","article-title":"Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence","volume":"261","author":"McGlone","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2026.101787_bib0044","first-page":"R975","article-title":"Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men","volume":"262","author":"Geary","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.diabet.2026.101787_bib0045","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2337\/db14-0242","article-title":"Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake","volume":"63","author":"Cegla","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0046","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0047","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0048","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"10.1016\/j.diabet.2026.101787_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2026.101787_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2026.101787_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0052","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0053","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101787_bib0054","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dbi19-0004","article-title":"Repositioning glucagon action in the physiology and pharmacology of diabetes","volume":"69","author":"Finan","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.diabet.2026.101787_bib0056","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2026.101787_bib0057","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101787_bib0058","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:09:05Z","timestamp":1790348945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1262363626000662"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101787","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower glucagon response and attenuated hepatic glucagon signaling in MASLD","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101787"}}